791.24
price down icon2.02%   -16.34
pre-market  Pre-market:  790.59   -0.65   -0.08%
loading
Lilly Eli Co stock is traded at $791.24, with a volume of 2.87M. It is down -2.02% in the last 24 hours and up +4.47% over the past month. Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$807.58
Open:
$805.16
24h Volume:
2.87M
Relative Volume:
0.73
Market Cap:
$724.64B
Revenue:
$49.00B
Net Income/Loss:
$11.11B
P/E Ratio:
64.38
EPS:
12.29
Net Cash Flow:
$-1.27B
1W Performance:
-1.98%
1M Performance:
+4.47%
6M Performance:
+1.62%
1Y Performance:
-10.60%
1-Day Range:
Value
$788.93
$805.16
1-Week Range:
Value
$788.93
$825.00
52-Week Range:
Value
$677.09
$972.53

Lilly Eli Co Stock (LLY) Company Profile

Name
Name
Lilly Eli Co
Name
Phone
(317) 276-2000
Name
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Name
Employee
47,000
Name
Twitter
@LillyPad
Name
Next Earnings Date
2024-10-30
Name
Latest SEC Filings
Name
LLY's Discussions on Twitter

Compare LLY with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - General icon
LLY
Lilly Eli Co
791.24 724.64B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
152.38 376.43B 89.33B 21.81B 18.57B 8.99
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
74.34 352.49B 43.59B 15.04B 10.74B 3.3766
Drug Manufacturers - General icon
ABBV
Abbvie Inc
185.48 334.73B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
116.41 234.21B 53.22B 12.86B 14.85B 6.39

Lilly Eli Co Stock (LLY) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-05-25 Downgrade Erste Group Buy → Hold
Apr-28-25 Downgrade HSBC Securities Buy → Reduce
Apr-22-25 Initiated Cantor Fitzgerald Overweight
Dec-10-24 Resumed BofA Securities Buy
Nov-15-24 Initiated Wolfe Research Outperform
Oct-17-24 Initiated Bernstein Outperform
Sep-13-24 Resumed Citigroup Buy
Aug-12-24 Upgrade Deutsche Bank Hold → Buy
Feb-21-24 Downgrade DZ Bank Buy → Hold
Feb-16-24 Reiterated Morgan Stanley Overweight
Dec-21-23 Downgrade Daiwa Securities Buy → Outperform
Nov-09-23 Initiated Deutsche Bank Hold
Oct-20-23 Resumed UBS Buy
Aug-09-23 Upgrade Jefferies Hold → Buy
Jul-26-23 Reiterated Citigroup Buy
Jul-14-23 Initiated HSBC Securities Buy
May-24-23 Reiterated BofA Securities Buy
May-24-23 Reiterated UBS Buy
Mar-13-23 Upgrade Wells Fargo Equal Weight → Overweight
Mar-06-23 Initiated Jefferies Hold
Feb-15-23 Downgrade Societe Generale Hold → Sell
Nov-18-22 Initiated Credit Suisse Outperform
Sep-22-22 Upgrade UBS Neutral → Buy
May-23-22 Initiated SVB Leerink Outperform
Apr-06-22 Resumed Morgan Stanley Overweight
Mar-10-22 Initiated Daiwa Securities Outperform
Jan-21-22 Upgrade DZ Bank Hold → Buy
Jan-03-22 Reiterated Bernstein Mkt Perform
Dec-17-21 Initiated Goldman Neutral
Dec-16-21 Reiterated BMO Capital Markets Outperform
Dec-16-21 Reiterated BofA Securities Buy
Dec-09-21 Resumed Wells Fargo Equal Weight
Nov-19-21 Initiated BMO Capital Markets Outperform
Oct-11-21 Upgrade Berenberg Hold → Buy
Sep-29-21 Upgrade Citigroup Neutral → Buy
Aug-05-21 Upgrade DZ Bank Hold → Buy
Jul-27-21 Resumed Truist Buy
Jun-24-21 Reiterated Cantor Fitzgerald Overweight
Jan-19-21 Upgrade Mizuho Neutral → Buy
Dec-10-20 Upgrade Wolfe Research Peer Perform → Outperform
Nov-10-20 Resumed Bernstein Mkt Perform
Sep-29-20 Initiated Berenberg Hold
Sep-03-20 Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-16-20 Upgrade Guggenheim Neutral → Buy
Apr-21-20 Downgrade UBS Buy → Neutral
Apr-09-20 Downgrade Morgan Stanley Overweight → Equal-Weight
Feb-06-20 Initiated Mizuho Neutral
Dec-18-19 Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-17-19 Resumed BofA/Merrill Buy
May-28-19 Initiated Goldman Buy
Apr-24-19 Upgrade Edward Jones Hold → Buy
Apr-11-19 Downgrade Guggenheim Buy → Neutral
Mar-12-19 Initiated JP Morgan Overweight
Jan-23-19 Initiated UBS Buy
Nov-26-18 Downgrade Citigroup Buy → Neutral
Oct-31-18 Upgrade Credit Suisse Underperform → Neutral
Oct-09-18 Initiated Guggenheim Buy
Oct-01-18 Reiterated SunTrust Buy
Sep-26-18 Resumed JP Morgan Overweight
View All

Lilly Eli Co Stock (LLY) Latest News

pulisher
07:19 AM

Eli Lilly to expand cardiovascular disease pipeline with $1.3bn Verve acquisition - PMLiVE

07:19 AM
pulisher
05:45 AM

Eli Lilly (LLY) Moves to Acquire Verve Therapeutics in $1B Deal - GuruFocus

05:45 AM
pulisher
05:38 AM

Eli Lilly acquisition of Verve signals renewed interest in gene editing - Investing.com

05:38 AM
pulisher
05:38 AM

Lilly Eyes Future of One-Time Cardiovascular Health with $1.3B Verve Therapeutics Acquisition - geneonline.com

05:38 AM
pulisher
03:38 AM

Adam Parker of Trivariate Research Recommends Eli Lilly’s Dividend as a Defensive Play - Insider Monkey

03:38 AM
pulisher
Jun 17, 2025

In a $1.3B deal, Lilly buys gene editor Verve - BioWorld MedTech

Jun 17, 2025
pulisher
Jun 17, 2025

Lilly Agrees To Acquire PCSK9 Base-Editing Partner Verve - insights.citeline.com

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly Co. to buy gene-editing startup Verve to develop cardiac drugs - upi.com

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly lands "bargain" deal to acquire Verve Therapeutics for $1.3bn - Pharmaceutical Technology

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly (LLY) 5-Year Growth Surges Over 383%, Showcasing Enduring Strength Beyond Daily Market Moves - Daily Chhattisgarh News

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly LLY (NYSE:LLY) Expands Biotech Reach With Verve Deal Talks Dow Jones Industrial Average - Kalkine Media

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion - WSJ

Jun 17, 2025
pulisher
Jun 17, 2025

UBS Maintains Price Target on Eli Lilly (LLY) Despite CVS Shift to Wegovy - Insider Monkey

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly Bets Big On Gene Editing With Verve Deal - Finimize

Jun 17, 2025
pulisher
Jun 17, 2025

Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly - TradingView

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly Acquires Verve Therapeutics In $1.3 Billion Deal - Finimize

Jun 17, 2025
pulisher
Jun 17, 2025

Lilly acquires cardiovascular genetic medicine company for up to $1.3B - Inside INdiana Business

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly to acquire gene-editing specialists focused on CVD for up to $1.3B - Cardiovascular Business

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly to buy Verve Therapeutics for up to $1.3 Billion - Yahoo

Jun 17, 2025
pulisher
Jun 17, 2025

Verve Therapeutics Soars 75% After Eli Lilly Buyout - Wall Street Pit

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly Expands Gene-Editing Arsenal With Verve Acquisition - Finimize

Jun 17, 2025
pulisher
Jun 17, 2025

Lilly adds highest Zepbound doses to DTC offering - statnews.com

Jun 17, 2025
pulisher
Jun 17, 2025

This one-and-done heart-disease treatment just got a $1.3 billion endorsement from Eli Lilly - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly to Buy Gene-Editing Biotech Verve for $1.3 Billion - Bloomberg

Jun 17, 2025
pulisher
Jun 17, 2025

Liking what it sees, Lilly to buy base editing partner Verve for $1.3B - FirstWord Pharma

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly Stock Dives Today: A Trader’s Analysis of Key LLY Metrics - Daily Chhattisgarh News

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly to acquire gene-editing biotech company Verve Therapeutics for $1.3 billion. Here's why - Mint

Jun 17, 2025
pulisher
Jun 17, 2025

Lilly to Acquire Verve Therapeutics for Up to $1.3B - Genetic Engineering and Biotechnology News

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly acquires biotech company for USD 1.3bn - medwatch.com

Jun 17, 2025
pulisher
Jun 17, 2025

Lilly to buy gene-editing partner Verve for up to US$1.3 billion in cardiac care push - CP24

Jun 17, 2025
pulisher
Jun 17, 2025

Verve soars after Eli Lilly announces $1.3 billion acquisition of gene-editing company - Sherwood News

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly to Acquire Verve Therapeutics to Advance One-Time Cardiovascular Treatments - CRISPR Medicine News

Jun 17, 2025
pulisher
Jun 17, 2025

Lilly spends $1B on Boston biotech developing gene-editing cholesterol drug - The Business Journals

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly to acquire Verve Therapeutics for USD 1.3 billion - Medical Dialogues

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly Expands Into Gene Editing With Verve Therapeutics Acquisition - Benzinga

Jun 17, 2025
pulisher
Jun 17, 2025

Lilly to buy gene-editing partner Verve for up to $1.3 billion in cardiac care push - Reuters

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly to buy gene-editing biotech Verve for up to $1.3 billion - statnews.com

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly (LLY) to Acquire Verve Therapeutics in $1.3 Billion De - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly to buy Verve Therapeutics for $1.3B - breakingthenews.net

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly to acquire gene-editing therapy developer Verve Therapeutics for up to $1.3 billion, companies say - marketscreener.com

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly to Acquire Gene-Editing Therapy Developer Verve Therapeutics for up to $1.3 Billion, Companies Say - U.S. News & World Report

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly Eyes $1.3 Billion Deal For Verve Therapeutics - Finimize

Jun 17, 2025
pulisher
Jun 17, 2025

Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk - Eli Lilly

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly & Co. (LLY) to acquire Verve Therapeutics (VERV) for $10.50/sh Cash plus CVR - StreetInsider

Jun 17, 2025
pulisher
Jun 17, 2025

Lilly's $1.3B Verve Acquisition Promises Revolutionary One-Shot Gene Therapy for Heart Disease - Stock Titan

Jun 17, 2025
pulisher
Jun 17, 2025

Media: Eli Lilly nears billion-dollar acquisition of gene editing biotech - medwatch.com

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly (LLY) Nears $1.3B Acquisition Deal for Verve Therapeutics - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly lining up $1.3bn swoop for cholesterol specialist Verve - Proactive financial news

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly expands Zepbound options for patients without health insurance - medwatch.com

Jun 17, 2025
pulisher
Jun 17, 2025

Eli Lilly, Juvena Therapeutics Partner to Develop Muscle-Boosting Drugs Using AI Platform - Insider Monkey

Jun 17, 2025

Lilly Eli Co Stock (LLY) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
drug_manufacturers_general JNJ
$152.38
price down icon 1.83%
drug_manufacturers_general NVO
$74.34
price down icon 3.48%
$185.48
price down icon 2.82%
drug_manufacturers_general NVS
$116.41
price down icon 1.42%
drug_manufacturers_general MRK
$78.28
price down icon 3.31%
Cap:     |  Volume (24h):